Heart attack patients may get safer blood thinners tailored to their genes

NCT ID NCT03729401

Terminated Disease control Sponsor: Ottawa Heart Institute Research Corporation Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether personalizing blood-thinning drugs based on a patient's genetics and risk factors could reduce bleeding after a heart attack. It enrolled 39 patients who had already been on standard dual therapy for a year. The trial was terminated early, so the findings are not conclusive.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Aspirin, Ticagrelor, Clopidogrel
What this could lead to: If successful, this could help doctors choose the safest blood-thinning drug for each patient after a heart attack, reducing bleeding side effects.
What could go wrong: The study was terminated early with very few participants (39 of 260 planned), so results are too limited to draw reliable conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE MYOCARDIAL INFARCTION

Contacts and locations

Show contact details

Locations

University of Ottawa Heart Institute

Ottawa, Ontario, K1Y4W7, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.